Solid-tumor mortality in the vicinity of uranium cycle facilities and nuclear power plants in Spain by Lopez-Abente, Gonzalo et al.
Environmental Health Perspectives • VOLUME 109 | NUMBER 7 | July 2001 721
Solid-Tumor Mortality in the Vicinity of Uranium Cycle Facilities and Nuclear
Power Plants in Spain
Gonzalo López-Abente, Nuria Aragonés, and Marina Pollán
Cancer Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain
The report that appeared in late 1983 of a
cluster of leukemias in young residents living
near a nuclear fuel reprocessing plant in
Sellafield, England, triggered a considerable
amount of investigation into cancer incidence
and mortality in areas near nuclear installa-
tions. The nuclear industry generates a great
deal of social concern, exacerbated recently by
the serious accidents that have affected nuclear
power plants, such as that of Chernobyl in
1986, and uranium processing facilities, such
as the one at Tokaimura in 1999.
Cancer incidence and mortality studies in
areas near nuclear facilities have failed to elim-
inate doubts about possible adverse popula-
tion effects attributable to routine operations,
despite the fact that numerous studies per-
formed in different countries have reported an
absence of cancer risk in areas around nuclear
fuel facilities and power plants (1–4). In the
main, epidemiologic studies have targeted
hematologic tumors and young age groups,
and very few have sought to assess in depth
the remaining malignant tumors. The con-
cern voiced by society regarding the conse-
quences of industry in its immediate vicinity
has essentially focused on nuclear power
plants. With respect to industries linked to
uranium production, considerable effort has
been made to ascertain the risk in cohorts of
miners (5–7), and although the environmen-
tal impact of nearby uranium mines, particu-
larly of uranium mill tailings (8–10), has been
studied, the related public health conse-
quences have received scant attention.
Spain currently has seven nuclear power
plants, with a total of 10 reactors (nine fully
operational and one being dismantled) and
nine nuclear fuel facilities (three fully opera-
tional, one shut down, and five being dis-
mantled). We therefore performed a cancer
mortality study covering towns near nuclear
power plants and fuel facilities. Death certifi-
cates were the only nationwide source of
information on mortality in Spain on which
a first analysis of this nature could be based. 
In a previous study we reported the
results for hematologic tumors (11). In this
article we report the results of that study for
solid tumors. The analysis presented here
sought to quantify the relative risk of death
in the vicinity of such installations; to ascer-
tain said risk before and after the date on
which these installations first came into
operation; to study changes in risk according
to subjects’ relative proximity to the respec-
tive installations; and, given the descriptive
and exploratory nature of this study, to pro-
vide further pointers for new research.
Materials and Methods
A more detailed description of the method-
ology may be found in a previous study
(11). Here we present results on mortality
caused by stomach cancer [International
Classification of Diseases-9 (ICD) 151] and
colorectal (ICD 153–154), lung (ICD 162),
bone (ICD 170), connective tissue (ICD
171), breast (in women, ICD 174), brain
(ICD 191), thyroid (ICD 193), bladder
(ICD 188), kidney (ICD 189), ovary (ICD
183), and all malignant tumors (ICD
140–208), in towns situated near nuclear
facilities. We included towns near four
nuclear power plants (NPP) with six reactors
that had been operational from 1975 to
1993, and four nuclear fuel facilities (NFF)
that had likewise been operational in the
same period. With the exception of El
Cabril, a nuclear waste storage facility
(NWSF) built on the site of an abandoned
uranium mine, the NFF are uranium-con-
centrate–processing facilities located in min-
ing areas where the ore is extracted. The
latency periods used were 10 years. This lag
rules out the possibility of study for the areas
surrounding the Ascó, Cofrentes, Trillo, and
Juzbado facilities, since all these plants were
inaugurated relatively recently. 
Figure 1 shows the site and year of start-
up of these installations. This was a spatial
mortality study whose population base com-
prised inhabitants of towns neighboring the
nuclear installations under review. For
description and analysis, the area within a
30-km radius of any such installation was
called the “exposed zone”; and towns
(selected as outlined below) lying within a
50- to 100-km radius of the installation
were called the “reference zone.” With a
Geographic Information System, we used
the UTM (Universal Transversa Mercator
projection) centroid coordinates for towns
to measure the distance from the population
centroids to the nuclear installations.
Follow-up took place from 1 January
1975 through 31 December 1993. For all
four nuclear power plants, 184 towns within
a 30-km radius and 178 within a 50- to 100-
km radius were included in the study,
matched by income level, number of inhabi-
tants, proportion of the active population
engaged in farming, proportion of unem-
ployed, percentage of illiteracy, and province.
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To ascertain solid tumor mortality in towns near Spain’s four nuclear power plants and four
nuclear fuel facilities from 1975 to 1993, we conducted a mortality study based on 12,245 cancer
deaths in 283 towns situated within a 30-km radius of the above installations. As nonexposed
areas, we used 275 towns lying within a 50- to 100-km radius of each installation, matched by
population size and sociodemographic characteristics (income level, proportion of active popula-
tion engaged in farming, proportion of unemployed, percentage of illiteracy, and province). Using
log-linear models, we examined relative risk for each area and trends in risk with increasing prox-
imity to an installation. The results reveal a pattern of solid-tumor mortality in the vicinity of
uranium cycle facilities, basically characterized by excess lung [relative risk (RR) 1.12, 95% confi-
dence interval (CI), 1.02–1.25] and renal cancer mortality (RR 1.37, 95% CI, 1.07–1.76).
Besides the effects of natural radiation, these results could well be evincing the influence on pub-
lic health exerted by the environmental impact of mining. No such well-defined pattern appeared
in the vicinity of nuclear power plants. Monitoring of cancer incidence and mortality is recom-
mended in areas surrounding nuclear fuel facilities and nuclear power plants, and more specific
studies are called for in areas adjacent to installations that have been fully operational for longer
periods. In this regard, it is important to use dosimetric information in all future studies. Key
words: environment, epidemiology, ionizing, mortality, neoplasms, nuclear facilities, radiation,
uranium mines. Environ Health Perspect 109:721–729 (2001). [Online 11 July 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p721-729lopez-abente/abstract.html
We selected reference towns at random from
among all those that met the matching con-
ditions. For all four nuclear fuel facilities, 99
and 97 towns in the exposed and reference
zones respectively were included in the study,
matched as above. The study covered
513,248 persons in the exposed zone for all
types of installations. We took sociodemo-
graphic data from the 1991 census (12) and
information on income levels from the
Spanish Market Yearbook (Anuario del
Mercado Español) (13).
Data specific to this study were supplied
on computer files by the National Statistics
Institute (Instituto Nacional de Estadística,
Madrid, Spain). Individual records were bro-
ken down by cause of death, sex, age group,
year of death, and town of residence. Town-
of-residence data for deceased persons are
treated as confidential in Spain for towns
having fewer than 10,000 inhabitants, so we
obtained special permission from the
National Statistics Institute for this study.
To obtain a population breakdown by
sex, age, and year for towns included in the
study, we referred to the 1981 population
census, 1986 municipal roll, and 1991 cen-
sus, as furnished by the National Statistics
Institute. Relying on a log-linear polynomial
regression model, we used interpolation to
estimate annual municipal population fig-
ures for 1981–1991 (14). We extrapolated
pre-1981 and post-1991 populations by
adopting a linear procedure, allocating more
weight to the nearest census year. With the
annual population estimates for each town,
we calculated person-years for each age band
(0–4, 5–14, 15–24, 25–34, 35–44, 45–54,
55–64, 65–74, 75+), sex, and period
(1975–1978, 1979–1983, 1984–1988,
1989–1993), taking into account variables
that had changed over time, such as opera-
tional start-up of reactors and installations. 
We fitted log-linear models  on the
assumption that the number of deaths per
stratum followed a Poisson distribution. In
these models, observed cases were the depen-
dent variable. As an external standard (15), we
used concurrent Spanish cause-specific mortal-
ity rates, with expected cases computed by age,
sex, and period for each town in the exposed
and reference (control) zones. Expected cases
were included as offset in the models. A term
we called “exposure” (a radius of 30 km or less
from the facility), was included as the inde-
pendent variable. The regression coefficient of
this exposure term gave us the logarithm of
the ratio between the respective standard mor-
tality ratios (SMRs) for the exposed and refer-
ence zones, which we called “relative risk”
(RR). This estimator was adjusted for age, sex,
period, and matching variables. 
We fitted similar models to study the
effect of distance on mortality. We
constructed this variable by categorizing dis-
tances in the 0- to 30-km belt into five levels
(consisting of circular sectors having equal
surface areas), and using towns situated at a
distance of 50–100 km as the reference level.
Expressed in kilometers, the cut-off points
for the intervals were 0–, 13.4–, 19.6–,
23.2–, 26.8–30, and 50–100. This was
included in all models both as a categoric
and as a continuous variable (in kilometers).
Thus, it was possible, for the former, to esti-
mate the effect for the respective distances
and, for the latter, to ascertain the existence
of radial effects (rise in RR with increasing
proximity to an installation) and, by apply-
ing the likelihood ratio test, the statistical
significance of such distance-induced effects.
The test was also applied to the 0–30-km
area with the reference area excluded. We
included matching variables in this analysis
to ensure control of possible gradients in
these variables with proximity to the installa-
tion. Given the heterogeneity of the installa-
tions, we ran specific analyses on individual
and a joint analysis on all installations. 
We studied changes in risk by compar-
ing the positions before and after the date on
which nuclear power plants and fuel facilities
first came into operation (start-up), taking
latency periods into account. These periods
were included in the assessment of risk
before start-up. The statistical significance of
this change was obtained following two cri-
teria:  fitting a model that compares the
SMRs before versus after start-up only for
the 0–30 km areas; and a likelihood ratio
test, which evaluates the interaction term—
exposure × plant operation—in regression
models, also including reference areas. The
former evaluates time trends in exposed areas
in contrast with trends at the national level,
and the latter evaluates time trend differ-
ences between exposed and unexposed areas
(reference areas).
We calculated relative risk confidence
intervals (CIs) using the standard errors of
the parameters yielded by the model. We
checked and corrected model results for
overdispersion problems (16) using the
robust methods recommended by Breslow,
because these methods are insensitive to the
form adopted by variance (17). 
Results
The socioeconomic characteristics and contri-
bution in terms of person-years of populations
residing near nuclear installations are described
elsewhere (11). According to the 1991 census,
the study population in the 30-km belt totaled
204,672 and 308,576 for nuclear power
plants and fuel facilities, respectively.
Tables 1 and 2 show the number of
observed deaths, SMRs, for the reference
zones and areas in a radius of 0–15 and 0–30
km of each installation, and the RRs and CIs
yielded by comparison with the reference
zones, for both sexes and across all age
groups, for the different causes studied.
Table 3  shows relative risk by distance from
the respective installations, for tumors caus-
ing at least 10 deaths in the study period.
The results of the pre- and poststart-up
analysis appear in Table 4.
In the vicinity of the Sta M. de Garoña
nuclear power plant (Burgos) (Table 1) an
RR of 1.34 (95% CI, 1.06–1.70) was
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Figure 1. Site and year of start-up of nuclear power plants and fuel facilities in Spain.
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Table 1. Comparison of cause-specific mortality in areas within a 15- and 30-km radius of nuclear power plants against that in reference (control) towns lying
within a radius of 50–100 km.
Control 0–15 km 0–30 km 0–15 km 0–30 km
Installation/cause Obs SMRa Obs SMRa Obs SMRa RRb 95% CI RRb 95% CI
All power plants
Lung 551 0.740 96 0.688 690 0.692 0.947 0.750–1.195 0.929 0.791–1.090
Bones 28 0.956 7 1.289 38 0.966 1.355 0.590–3.112 0.967 0.593–1.577
Breast (women) 206 0.834 23 0.538 298 0.911 0.633 0.412–0.974 1.066 0.892–1.273
Brain 116 1.371 8 0.529 128 1.128 0.376 0.183–0.770 0.833 0.647–1.072
Thyroid 11 0.921 0 0.000 8 0.507 0.000 – 0.543 0.218–1.353
Bladder 142 0.800 21 0.619 197 0.835 0.788 0.498–1.246 1.028 0.829–1.276
Ovary 40 0.771 3 0.336 55 0.804 0.450 0.141–1.436 1.021 0.678–1.536
Connective tissue 10 0.655 3 1.120 24 1.180 1.970 0.536–7.243 1.903 0.908–3.986
Kidney 66 1.089 14 1.251 75 0.931 1.178 0.660–2.102 0.845 0.607–1.178
Stomach 460 1.088 86 1.076 612 1.085 0.989 0.761–1.285 1.019 0.879–1.182
Colorectal 360 0.880 67 0.883 483 0.892 0.995 0.766–1.293 1.010 0.881–1.158
All cancers 3,552 0.854 598 0.775 4,686 0.846 0.911 0.825–1.006 0.987 0.918–1.063
Zorita (1979–1993)
Lung 128 0.621 35 0.644 145 0.647 1.038 0.683–1.577 1.042 0.814–1.332 
Bones 7 0.804 2 0.874 7 0.741 1.087 0.227–5.205 0.922 0.324–2.620 
Breast (women) 52 0.812 12 0.717 49 0.734 0.884 0.475–1.646 0.905 0.614–1.334 
Brain 42 1.790 2 0.327 26 1.068 0.183 0.044–0.752 0.597 0.366–0.973 
Thyroid 4 1.238 0 0.000 2 0.571 0.000 – 0.461 0.085–2.509 
Bladder 35 0.690 8 0.600 47 0.825 0.870 0.404–1.871 1.195 0.773–1.848 
Ovary 9 0.683 1 0.290 8 0.585 0.425 0.055–3.278 0.856 0.331–2.216 
Connective tissue 0 0.000 2 1.993 6 1.484 – – – –
Kidney 16 0.969 3 0.690 13 0.723 0.713 0.208–2.445 0.747 0.359–1.552 
Stomach 145 1.174 36 1.099 161 1.167 0.936 0.648–1.351 0.994 0.785–1.259 
Colorectal 91 0.810 31 1.046 117 0.943 1.291 0.859–1.940 1.164 0.886–1.531 
All cancers 947 0.817 247 0.810 1,040 0.820 0.991 0.859–1.143 1.003 0.901–1.118 
Garoña (1981–1993)
Lung 208 0.762 16 0.410 234 0.613 0.538 0.324–0.894 0.805 0.668–0.970 
Bones 11 0.990 0 0.000 7 0.460 0.000 – 0.465 0.180–1.199
Breast (women) 75 0.808 3 0.282 104 0.819 0.349 0.113–1.076 1.014 0.753–1.364
Brain 46 1.441 2 0.525 50 1.134 0.364 0.089–1.485 0.786 0.528–1.170
Thyroid 5 1.128 0 0.000 2 0.328 0.000 – 0.291 0.057–1.495
Bladder 55 0.854 5 0.503 64 0.717 0.590 0.238–1.458 0.839 0.586–1.203
Ovary 16 0.826 0 0.000 14 0.527 0.000 – 0.638 0.312–1.305
Connective tissue 7 1.235 1 1.495 6 0.776 1.211 0.149–9.814 0.628 0.212–1.865
Kidney 27 1.215 3 0.971 31 1.007 0.799 0.242–2.631 0.828 0.494–1.387
Stomach 170 1.082 38 1.667 314 1.448 1.541 1.057–2.247 1.338 1.055–1.698
Colorectal 111 0.739 13 0.609 161 0.778 0.823 0.464–1.461 1.053 0.827–1.341
All cancers 1,354 0.882 128 0.597 1,709 0.805 0.677 0.535–0.857 0.913 0.776–1.075
Vandellós (1982–1993)
Lung 163 0.793 38 1.006 264 0.790 1.269 0.963–1.672 0.996 0.768–1.292
Bones 9 1.140 5 3.409 22 1.675 2.989 1.003–8.904 1.469 0.679–3.180 
Breast (women) 65 0.937 7 0.549 131 1.156 0.586 0.277–1.240 1.233 0.889–1.711
Brain 22 0.949 4 0.909 46 1.175 0.958 0.330–2.780 1.239 0.593–2.587
Thyroid 2 0.609 0 0.000 4 0.763 0.000 – 1.254 0.230–6.842
Bladder 41 0.845 7 0.809 79 1.033 0.958 0.430–2.133 1.223 0.839–1.781
Ovary 10 0.685 1 0.378 29 1.227 0.551 0.071–4.290 1.792 0.879–3.653
Connective tissue 3 0.694 0 0.000 5 0.692 0.000 – 0.997 0.241–4.120 
Kidney 18 1.077 8 2.638 26 0.968 2.450 1.066–5.633 0.899 0.493–1.638
Stomach 102 0.894 10 0.488 112 0.613 0.546 0.285–1.045 0.686 0.510–0.924
Colorectal 126 1.121 19 0.945 171 0.960 0.843 0.567–1.254 0.857 0.669–1.097
All cancers 980 0.858 187 0.901 1,656 0.900 1.050 0.925–1.193 1.049 0.946–1.163
Almaraz (1991–1993)
Lung 52 0.863 7 0.823 47 0.824 0.953 0.384–2.368 0.954 0.619–1.469
Bones 1 0.631 0 0.000 2 1.296 0.000 – 2.054 0.189–22.370
Breast (women) 14 0.678 1 0.378 14 0.703 0.557 0.074–4.180 1.036 0.494–2.172
Brain 6 0.994 0 0.000 6 1.025 0.000 – 1.032 0.333–3.199
Bladder 11 0.788 1 0.502 7 0.528 0.638 0.085–4.795 0.670 0.260–1.726
Ovary 5 1.064 1 1.636 4 0.885 1.537 0.182–12.989 0.832 0.223–3.097
Connective tissue 0 0.000 0 0.000 7 5.215 – –
Kidney 5 0.969 0 0.000 5 1.016 0.000 – 1.048 0.303–3.620 
Stomach 43 1.537 2 0.517 25 0.939 0.337 0.083–1.372 0.611 0.339–1.100 
Colorectal 32 0.932 4 0.845 34 1.039 0.907 0.321–2.564 1.115 0.688–1.807
All cancers 271 0.843 36 0.812 281 0.917 0.964 0.693–1.340 1.087 0.894–1.322
Obs, Observed cases. Latency period of 10 years.
aSMR is the ratio of the number of deaths observed and expected at concurrent death rates in Spain. bRR compares the risk in study versus control areas. The RR for combined facilities
is obtained from a regression model including the facilities as a factor, and differs from the simple ratio of the SMRs. 
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Table 2. Comparison of cause-specific mortality in areas within a 15- and 30-km radius of nuclear fuel facilities against that in reference (control) towns lying
within a radius of 50–100 km.
Control 0–15 km 0–30 km 0–15 km 0–30 km
Installation/cause Obs SMRa Obs SMRa Obs SMRa RRb 95% CI RRb 95% CI
Nuclear fuel facilities
Lung 1,429 0.895 379 0.915 1,424 1.022 1.123 0.953–1.324 1.124 1.015–1.246
Bones 51 0.685 18 0.918 66 1.017 1.209 0.699–2.091 1.512 1.048–2.182
Breast (women) 471 0.789 122 0.805 436 0.858 1.059 0.783–1.432 1.077 0.921–1.259
Brain 185 0.879 41 0.740 140 0.777 0.862 0.609–1.220 0.875 0.702–1.090
Thyroid 17 0.619 7 0.998 24 1.002 1.721 0.693–4.274 1.604 0.860–2.993
Bladder 331 0.887 56 0.581 251 0.760 0.707 0.531–0.943 0.837 0.690–1.015
Ovary 70 0.578 22 0.720 95 0.925 1.481 0.895–2.449 1.525 1.119–2.078
Connective tissue 38 1.100 4 0.452 20 0.684 0.462 0.163–1.313 0.608 0.353–1.046
Kidney 114 0.856 32 0.932 136 1.171 1.220 0.816–1.825 1.374 1.071–1.763
Stomach 892 0.892 225 0.869 752 0.849 0.930 0.782–1.105 0.963 0.865–1.073
Colorectal 667 0.733 199 0.853 677 0.847 1.205 0.989–1.470 1.153 1.009–1.317
All cancers 8,124 0.870 2,139 0.889 7,559 0.927 1.064 0.964–1.175 1.056 1.000–1.114
Andújar (1975–1993)
Lung 686 0.768 291 0.927 670 0.954 1.207 1.000–1.456 1.242 1.056–1.461
Bones 39 0.821 15 0.899 39 1.039 1.095 0.604–1.984 1.265 0.813–1.970 
Breast (women) 237 0.705 97 0.838 206 0.790 1.188 0.856–1.649 1.121 0.887–1.416
Brain 111 0.877 34 0.749 75 0.747 0.854 0.605–1.205 0.851 0.641–1.130 
Thyroid 8 0.517 4 0.756 8 0.663 1.461 0.444–4.810 1.281 0.481–3.413
Bladder 160 0.759 42 0.583 113 0.688 0.768 0.581–1.015 0.906 0.718–1.145
Ovary 25 0.382 18 0.797 43 0.848 2.087 1.141–3.819 2.220 1.358–3.628
Connective tissue 16 0.868 4 0.606 10 0.683 0.698 0.234–2.082 0.787 0.359–1.722
Kidney 56 0.760 18 0.702 52 0.899 0.924 0.543–1.570 1.184 0.812–1.726
Stomach 524 0.858 174 0.836 377 0.791 0.975 0.805–1.180 0.922 0.792–1.073
Colorectal 342 0.672 138 0.795 320 0.806 1.183 0.904–1.549 1.200 0.966–1.491
All cancers 4,282 0.799 1,617 0.873 3,646 0.870 1.093 0.970–1.231 1.088 1.002–1.183
El Cabrilc (1975–1993)
Lung 259 1.124 – – 351 1.210 – – 1.077 0.858–1.351
Bones 5 0.410 – – 15 0.979 – – 2.389 0.870–6.557
Breast (women) 64 0.742 – – 117 1.094 – – 1.476 1.085–2.007
Brain 34 1.020 – – 37 0.964 – – 0.945 0.594–1.506
Thyroid 2 0.506 – – 6 1.149 – – 2.270 0.459–11.236
Bladder 55 1.035 – – 73 1.010 – – 0.976 0.661–1.442
Ovary 17 1.009 – – 30 1.456 – – 1.443 0.796–2.615
Connective tissue 5 1.018 – – 9 1.618 – – 1.590 0.533–4.744
Kidney 13 0.685 – – 31 1.279 – – 1.866 0.853–4.082
Stomach 100 0.651 – – 161 0.763 – – 1.171 0.911–1.505
Colorectal 93 0.720 – – 152 0.874 – – 1.214 0.940–1.567
All cancers 1,269 0.928 – – 1,845 1.037 – – 1.117 0.993–1.257
La Haba (1987–1993)
Lung 421 1.141 49 0.842 336 1.103 0.738 0.553–0.984 0.967 0.835–1.120 
Bones 7 0.578 1 0.553 10 1.044 0.957 0.118–7.764 1.806 0.691–4.718 
Breast (women) 150 1.068 10 0.481 87 0.798 0.451 0.187–1.089 0.747 0.554–1.009 
Brain 33 0.804 4 0.678 25 0.769 0.844 0.302–2.363 0.957 0.569–1.608 
Thyroid 5 0.792 3 2.998 9 1.782 3.787 0.905–15.838 2.251 0.755–6.713 
Bladder 98 1.174 7 0.497 54 0.777 0.424 0.158–1.134 0.662 0.396–1.104 
Ovary 21 0.680 3 0.650 20 0.827 0.956 0.285–3.199 1.216 0.660–2.243 
Connective tissue 16 1.781 0 0.000 1 0.143 0.000 – 0.080 0.011–0.602 
Kidney 44 1.400 13 2.595 49 1.911 1.853 0.999–3.439 1.365 0.852–2.189 
Stomach 183 0.983 31 1.021 162 1.070 1.038 0.709–1.519 1.088 0.881–1.344 
Colorectal 184 0.874 43 1.248 163 0.954 1.428 1.025–1.989 1.091 0.870–1.369 
All cancers 2,117 1.036 315 0.968 1,662 1.002 0.935 0.817–1.070 0.967 0.894–1.047 
Ciudad Rodrigo (1989–1993)
Lung 63 0.603 39 0.930 67 0.699 1.544 1.036–2.302 1.160 0.764–1.762 
Bones 0 0.000 2 1.812 2 0.824 – – – –
Breast (women) 20 0.586 15 1.005 26 0.819 1.716 0.879–3.351 1.398 0.781–2.505 
Brain 7 0.725 3 0.732 3 0.341 1.010 0.262–3.894 0.471 0.122–1.820 
Thyroid 2 1.162 0 0.000 1 0.621 0.000 – 0.534 0.048–5.879 
Bladder 18 0.694 7 0.683 11 0.453 0.984 0.411–2.356 0.653 0.309–1.382 
Ovary 7 0.893 1 0.297 2 0.277 0.332 0.042–2.646 0.310 0.065–1.492 
Connective tissue 1 0.454 0 0.000 0 0.000 – – – –
Kidney 1 0.110 1 0.271 4 0.475 2.463 0.154–39.367 4.314 0.496–37.546
Stomach 85 1.704 20 0.982 52 1.110 0.576 0.354–0.938 0.651 0.461–0.920 
Colorectal 48 0.779 18 0.714 42 0.725 0.917 0.533–1.576 0.930 0.615–1.407 
All cancers 456 0.809 207 0.898 406 0.774 1.109 0.885–1.391 0.956 0.745–1.226 
Obs, Observed cases. Latency period of 10 years.
aSMR is the ratio of the number of deaths observed and expected at concurrent death rates in Spain. bRR compares the risk in study versus control areas. The RR for combined facilities
is obtained from a regression model including the facilities as a factor, and differs from the simple ratio of the SMRs. cNo towns within 15 km of the installation. 
observed for stomach cancer, with the relative
risk similar for men and women (data not
shown). In Vandellós, excess renal and bone
cancer was in evidence in the 15-km belt. For
the Zorita area, six deaths occurred from con-
nective tissue tumors, versus no deaths in the
reference area. Four of these were men and
two were women. Four of the cases resided in
towns more than 19 km from the plant.
Almaraz had somewhat similar conditions,
with seven deaths from connective tissue
tumors versus none in the reference area. Six
of these cases were men and occurred in
towns lying 26–30 km from the plant. Three
people died before start-up (Table 4).
Overall, we observed no excess mortality
for tumor sites as a whole in areas around
nuclear power plants in Spain (Table 1). The
highest relative risk was registered for con-
nective tissue tumors (RR 1.90 95%; CI,
0.91–3.99), with 13 cases reported in the
Almaraz and Zorita areas.
In the near-versus-far analysis of all fuel
cycle facilities as a whole (Table 2), we
detected statistically significant excess mor-
tality for lung, bone, ovarian, renal, and col-
orectal cancer. 
Examination of the results by facility
showed excess cancer mortality of almost
9% in the area surrounding the Andújar
plant. This excess was attributable to higher-
than-expected lung, ovarian, and colorectal
cancer mortality.
The El Cabril area registered a statisti-
cally significant excess breast cancer mortal-
ity among women (RR 1.48; 95% CI,
1.09–2.01). Comparison between the 15-km
radius around the La Haba plant and the ref-
erence area showed a higher risk of colorectal
cancer mortality (RR 1.43; 95% CI,
1.03–1.49), an RR of 1.85 (95% CI,
1.00–3.44) for renal cancer, and an RR of
3.79 (95% CI, 0.91–15.84) for thyroid can-
cer. Renal cancer registered an SMR that was
almost 2 vis-à-vis the national reference and
was statistically significant. 
The most noteworthy finding in the
Ciudad Rodrigo area was the higher risk of
death from lung cancer observed for all
towns nearest (0–15 km) the installation
(RR 1.54; 95% CI, 1.04–2.30).
The RR point estimator for renal cancer
exceeded 1 for all areas surrounding uranium
cycle facilities. Overall, we observed excess
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Table 3. Relative risks according to distance of population centroids from nuclear power plants and fuel facilities, with test for trend. 
p-Value for trend
Reference > 50 km Distance Exposed area Exposed and 
Installation/cause 26.8–30 km 23.2–26.7 km 19–23.1 km 13.4–18.9 km 0–13.3 km only reference areas
All power plants
Lung 0.816 0.896 1.034 0.827 1.049 0.4881 0.0854
Bones 0.541 1.223 1.026 1.215 1.595 0.1210 0.6447
Breast (women) 0.965 1.108 1.233 1.008 0.721 0.3767 0.3594
Brain 0.870 0.415 0.912 0.993 0.427 0.1993 0.1802
Bladder 1.096 1.231 1.039 0.982 0.728 0.1612 0.8061
Ovary 0.844 1.345 0.961 1.527 0.521 0.7689 0.2773
Kidney 0.588 0.404 0.798 1.478 1.284 0.0065 0.2872
Stomach 1.042 0.980 0.992 1.074 1.004 0.9288 0.9314
Colorectal 1.129 0.917 0.992 0.916 1.010 0.3452 0.8983
All cancers 0.929 0.984 1.021 1.030 0.961 0.4573 0.2080
Zorita
Lung 1.052 0.982 1.258 0.892 1.136 0.9719 0.8483
Breast (women) 1.008 0.633 0.938 0.649 0.981 0.9948 0.4642
Brain 0.893 0.000 0.599 1.556 0.194 0.2467 0.4857
Bladder 1.393 1.197 1.601 0.918 0.876 0.2522 0.5501
Kidney 0.296 0.737 0.678 3.150 0.549 0.3246 0.2937
Stomach 1.263 0.947 0.981 0.951 0.983 0.2101 0.5722
Colorectal 1.220 0.984 1.274 1.188 1.230 0.9011 0.1626
All cancers 0.978 0.973 1.094 1.046 1.013 0.7640 0.8231
Garoña
Lung 0.559 0.854 0.957 0.905 0.727 0.0903 0.0631
Breast (women) 0.652 0.492 1.232 0.769 0.693 0.0787 0.3924
Brain 0.889 0.925 0.899 0.313 0.515 0.3521 0.2508
Bladder 0.615 0.665 0.505 0.970 0.611 0.9103 0.0128
Kidney 0.686 0.002 0.714 0.492 1.527 0.1577 0.2624
Stomach 1.215 1.455 1.206 1.643 1.749 0.0280 0.0036
Colorectal 1.092 1.772 1.087 0.714 0.829 0.1475 0.7998
All cancers 0.808 0.948 0.880 0.862 0.846 0.2270 0.0001
Vandellós
Lung 0.904 1.067 1.104 1.058 1.315 0.5478 0.7494
Bones 0.808 3.519 1.632 3.054 3.622 0.0740 0.0432
Breast (women) 1.540 1.607 1.162 1.001 0.519 0.0296 0.3359
Brain 1.123 1.012 1.862 1.290 1.415 0.3156 0.6061
Bladder 1.407 1.733 1.085 0.907 0.952 0.5487 0.4473
Ovary 1.673 3.040 1.494 3.554 0.427 0.1842 0.6466
Kidney 0.463 0.193 0.555 0.839 2.039 0.0019 0.4970
Stomach 0.764 0.870 0.715 1.065 0.553 0.8251 0.0344
Colorectal 1.272 0.752 0.732 0.910 0.918 0.2919 0.7669
All cancers 1.068 1.106 1.068 1.139 1.044 0.7296 0.0849
Almaraz
Lung 0.742 0.001 1.376 0.739 1.443 0.6561 0.4659
Breast (women) 1.629 3.496 1.174 0.785 0.766 0.3761 0.7295
Stomach 0.371 0.001 0.199 1.207 0.541 0.7098 0.0249
Colorectal 0.947 0.001 3.064 0.842 0.940 0.3765 0.6772
All cancers 0.988 0.378 1.393 1.055 1.102 0.3850 0.7145
continued, next page
cancer mortality (for all tumor sites as a
whole) for fuel cycle facilities, in great mea-
sure reflecting excess lung cancer among men.
Analysis of mortality in relation to dis-
tance from any given installation yielded
results that differed widely according to the
radius of application of the statistical test used.
Two different tests are included in Table 3:
The first ascertains the statistical significance
of the slope of relative risk solely in the
exposed area, whereas the second addresses the
entire study area. In Garoña, stomach cancer
plotted a statistically significant gradient with
both tests. Similarly, for bone cancer, there
appears to be a risk gradient proportional to
the proximity to Vandellós. For renal cancer
in Garoña and Vandellós, the highest risks
corresponded to the area closest to the instal-
lation, thus accounting for the statistical sig-
nificance of the test for the exposed area in
Vandellós and for the joint analysis of all
four nuclear power plants (Table 3).
The different limitations of these two sta-
tistical tests can be observed better in Table
3, in which analysis of all fuel cycle facilities
is displayed jointly. The statistical signifi-
cance of the test covering the entire study
area is in sharp contrast to the RR estimators
for the different distances, in that these show
no gradient with proximity to the installa-
tion. None of the statistical tests covering the
entire study area were confirmed when
applied to the 30-km radius. The El Cabril
risk estimators for renal cancer were deter-
mined by the low number of cases in towns
lying nearest the plant and the stringent
stratification applied in the analysis. The
greatest number of cases (22 of 31) occurred
in the most distant towns (> 26 km), so that
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Table 3 (continued). 
p-Value for trend
Reference > 50 km Distance Exposed area Exposed and 
Installation/Cause 26.8–30 km 23.2–26.7 km 19–23.1 km 13.4–18.9 km 0–13.3 km only reference areas
Nuclear fuel facilities
Lung 1.077 1.164 1.073 1.172 1.113 0.6564 0.2313
Bones 1.953 1.487 1.276 1.816 1.233 0.2510 0.0353
Breast (women) 0.920 1.487 1.014 0.979 1.182 0.1435 0.7317
Brain 0.898 0.603 0.838 1.026 0.866 0.8540 0.1153
Thyroid 1.880 0.002 1.852 1.937 1.402 0.5036 0.1987
Bladder 0.744 1.090 0.778 1.026 0.713 0.6837 0.0098
Ovary 1.821 1.563 1.451 1.058 1.485 0.2658 0.0209
Kidney 1.434 2.113 1.210 1.327 1.317 0.3683 0.0066
Stomach 0.916 1.028 1.026 0.939 0.962 0.7711 0.7905
Colorectal 1.072 1.361 1.045 1.268 1.121 0.9606 0.0510
All cancers 1.010 1.139 1.014 1.073 1.073 0.3005 0.1819
Andújar
Lung 1.060 1.361 1.254 1.415 1.106 0.7278 0.1446
Bones 2.189 2.329 0.966 1.721 1.484 0.4531 0.0852
Breast (women) 0.778 1.126 1.115 2.052 1.188 0.1533 0.4396
Brain 0.810 0.732 1.006 0.414 0.796 0.7472 0.2566
Bladder 1.096 0.952 0.907 1.536 0.792 0.5245 0.2361
Ovary 2.204 3.464 2.325 1.439 2.381 0.8357 0.0010
Kidney 2.013 2.013 1.054 0.437 1.019 0.0455 0.3409
Stomach 0.919 1.045 0.955 0.606 1.059 0.7610 0.7349
Colorectal 1.349 1.377 1.110 1.737 1.232 0.9096 0.0716
All cancers 1.026 1.127 1.091 1.277 1.087 0.3930 0.0305
El Cabril
Lung 0.880 1.941 0.689 1.922 – 0.5973 0.6611
Bones 2.283 0.039 9.312 31.621 – 0.6478 0.0769
Breast (women) 1.276 6.283 1.694 3.320 – 0.8897 0.1916
Brain 0.940 1.027 0.892 1.481 – 0.5623 0.6127
Bladder 0.574 1.305 0.644 2.207 – 0.3417 0.0125
Ovary 1.702 3.376 0.169 1.186 – 0.2202 0.3496
Kidney 4.620 6.760 10.837 11.892 – 0.5855 0.0015
Stomach 0.898 1.848 0.957 2.806 – 0.1553 0.8829
Colorectal 0.996 2.060 1.234 1.487 – 0.5405 0.5016
All cancers 0.962 2.202 0.921 1.587 – 0.5087 0.9713
La Haba
Lung 0.943 0.856 1.101 0.956 0.920 0.8782 0.4601
Bones 3.590 0.002 1.299 1.651 0.001 0.3149 0.1859
Breast (women) 0.817 0.728 1.048 0.648 0.768 0.6401 0.0188
Brain 0.396 0.003 0.906 1.094 1.136 0.2393 0.4265
Bladder 0.586 2.290 0.416 0.811 0.373 0.5640 0.1575
Ovary 1.807 0.010 2.611 0.919 1.068 0.3564 0.3906
Kidney 0.995 0.002 1.653 1.330 3.281 0.2138 0.0498
Stomach 0.921 1.402 1.364 1.010 1.130 0.9893 0.5535
Colorectal 1.002 0.001 1.042 1.198 1.260 0.2678 0.3414
All cancers 0.910 0.781 1.073 0.961 1.089 0.2641 0.3495
Ciudad Rodrigo
Lung 0.714 0.582 1.851 1.334 1.493 0.0502 0.1446
Breast (women) 0.593 1.266 0.737 2.287 1.742 0.3510 0.1627
Bladder 0.000 1.090 1.007 0.000 0.799 0.6358 0.3950
Stomach 0.784 0.874 0.806 0.671 0.518 0.3541 0.0173
Colorectal 1.183 1.007 0.268 1.588 0.987 0.9753 0.9677
All cancers 0.889 0.974 1.029 0.964 1.061 0.9377 0.6539
Only tumor sites with 10 or more observed deaths are shown. Estimates have been adjusted for matching variables. The most distant towns (radius 50–100 km) are taken as reference.
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Table 4. Estimated relative risk for study areas (0–30 km) before and after the date on which nuclear facilities first came into operation (before and after start-up). 
Before start-up After start-up After vs. before start-up Trend differences
Installation/cause Obs SMRa Obs SMR RRb p-Value p-Valuec
Zorita 1975–1978d 1979–1993 
Lung 21 0.435 145 0.647 1.486 0.0893 0.9677
Bones 7 1.752 7 0.741 0.423 0.1070 0.7483
Breast (women) 9 0.576 49 0.734 1.274 0.5008 0.9585
Brain 8 1.135 26 1.068 0.942 0.8815 0.2386
Thyroid 0 0.000 2 0.571 – 0.7805 0.3726
Bladder 5 0.346 47 0.825 2.384 0.0617 0.1470
Ovary 1 0.472 8 0.585 1.240 0.8393 _e
Connective tissue 0 0.000 6 1.484 – 0.7687 –
Kidney 4 1.014 13 0.723 0.713 0.5540 0.1634
Stomach 67 1.159 161 1.167 1.008 0.9579 0.7370
Colorectal 27 0.791 117 0.943 1.192 0.4095 0.5082
All cancers 269 0.777 1,040 0.820 1.055 0.4310 0.4772
Garoña 1975–1980 1981–1993 
Lung 53 0.425 234 0.613 1.443 0.0158 0.4047
Bones 7 0.685 7 0.460 0.672 0.4566 0.6727
Breast (women) 35 0.760 104 0.819 1.077 0.7027 0.9374
Brain 22 0.982 50 1.134 1.154 0.5745 0.5616
Thyroid 0 0.000 2 0.328 – 0.6062 –
Bladder 20 0.620 64 0.717 1.156 0.5691 0.3785
Ovary 6 0.858 14 0.527 0.614 0.3179 0.1555
Connective tissue 1 0.560 6 0.776 1.386 0.7613 –
Kidney 4 0.396 31 1.007 2.544 0.0785 0.6044
Stomach 152 1.197 314 1.448 1.210 0.0539 0.0700
Colorectal 53 0.683 161 0.778 1.140 0.4070 0.4535
All cancers 632 0.743 1,709 0.805 1.084 0.0840 0.3868
Vandellós 1975–1981 1982–1993
Lung 80 0.583 264 0.790 1.355 0.0173 0.7829
Bones 7 0.631 22 1.675 2.655 0.0232 0.2687
Breast (women) 20 0.399 131 1.156 2.893 0.0000 0.0028
Brain 28 1.085 46 1.175 1.083 0.7370 0.5890
Thyroid 2 0.815 4 0.763 0.936 0.9387 –
Bladder 26 0.753 79 1.033 1.372 0.1615 0.8312
Ovary 4 0.513 29 1.227 2.392 0.1003 0.0812
Connective tissue 2 0.935 5 0.692 0.740 0.7167 0.9176
Kidney 13 1.178 26 0.968 0.822 0.5613 0.1109
Stomach 80 0.608 112 0.613 1.009 0.9509 0.2727
Colorectal 64 0.792 171 0.960 1.213 0.1873 0.6208
All cancers 683 0.747 1,656 0.900 1.205 0.0000 0.7180
Almaraz 1975–1990 1991–1993
Lung 244 1.075 47 0.824 0.766 0.0943 0.4455
Bones 10 0.738 2 1.296 1.757 0.4662 0.3927
Breast (women) 62 0.750 14 0.703 0.937 0.8265 0.6404
Brain 24 0.718 6 1.025 1.428 0.4354 0.4406
Thyroid 2 0.504 0 0.000 0.000 0.8094 –
Bladder 31 0.559 7 0.528 0.945 0.8918 0.4909
Ovary 13 0.849 4 0.885 1.043 0.9413 0.6632
Connective tissue 3 0.675 7 5.215 7.730 0.0030 –
Kidney 21 1.132 5 1.016 0.897 0.8276 0.9145
Stomach 216 1.261 25 0.939 0.744 0.1616 0.2143
Colorectal 104 0.793 34 1.039 1.311 0.1708 0.1766
All cancers 1,359 0.968 281 0.917 0.947 0.4010 0.3964
La Haba 1975–1986 1987–1993
Lung 424 1.106 336 1.103 0.997 0.9769 0.7334
Bones 33 1.227 10 1.044 0.851 0.6533 0.4513
Breast (women) 136 0.923 87 0.798 0.865 0.2901 0.4998
Brain 54 0.834 25 0.769 0.922 0.7361 0.8611
Thyroid 2 0.289 9 1.782 6.173 0.0198 0.0364
Bladder 51 0.556 54 0.777 1.397 0.0866 0.2231
Ovary 19 0.741 20 0.827 1.116 0.7312 0.6459
Connective tissue 2 0.288 1 0.143 0.495 0.5651 0.4995
Kidney 30 0.969 49 1.911 1.973 0.0033 0.1476
Stomach 346 1.082 162 1.070 0.989 0.9054 0.3746
Colorectal 215 0.976 163 0.954 0.977 0.8264 0.9546
All cancers 2,301 0.937 1,662 1.002 1.069 0.0389 0.0727
Ciudad Rodrigo 1975–1988 1989–1993
Lung 103 0.511 67 0.699 1.370 0.0451 0.1229
Bones 14 1.121 2 0.824 0.735 0.6840 –
Breast (women) 53 0.770 26 0.819 1.063 0.7993 0.7471
Brain 35 1.283 3 0.341 0.266 0.0256 0.0875
Thyroid 1 0.284 1 0.621 2.184 0.5807 0.7158
Bladder 28 0.525 11 0.453 0.863 0.6781 0.1765
Ovary 5 0.411 2 0.277 0.675 0.6383 0.5592
Connective tissue 1 0.297 0 0.000 0.000 0.7792 –
Kidney 17 1.050 4 0.475 0.453 0.1484 0.1459
Stomach 250 1.491 52 1.110 0.745 0.0530 0.0478
Colorectal 111 0.922 42 0.725 0.786 0.1842 0.5707
All cancers 1,052 0.821 406 0.774 0.942 0.3034 0.9700
Obs, observed deaths. aSMR is the ratio of the number of deaths observed and expected at concurrent death rates in Spain. bRR compares SMRs after versus before start-up in the
exposed areas; p-value corresponds to the statistical significance of this RR. cStatistical significance for time trend differences between exposed and unexposed areas. dYears
included. eNo cases in the reference area. 
estimates in the nearest sectors were made on
the basis of 2, 4, and 3 deaths respectively and
thus exhibit a very low degree of accuracy.
Analysis of nuclear power plants before
and after start-up in Garoña showed an
increase in stomach cancer after the plant
began operating, though this increase was
just on the limit of statistical significance
(Table 4). In Vandellós, we observed a rise in
breast cancer mortality in women after the
plant’s commissioning, and in Almaraz an
increase of connective tissue cancer mortality.
Regarding uranium cycle facilities, no statisti-
cally significant changes could be demon-
strated for any of the tumors studied, except
for thyroid cancer in the vicinity of La Haba. 
In evaluating time trends, it is advisable to
highlight the different results obtained by the
two analyses proposed. Thus, lung cancer
mortality showed a greater increase in the
exposed areas of Garoña, Vandellós, and
Zorita, compared with the national trend, and
the same was true for renal cancer in La Haba.
However, it would be risky to attribute these
increases to the effect of the nuclear facilities,
since the corresponding unexposed areas pre-
sented a similar pattern, as is suggested by the
p-value in the last column of Table 4. 
Discussion
Overall, the results of the study indicate a
cancer mortality pattern in areas adjacent to
uranium cycle facilities that is basically char-
acterized by excess deaths due to renal and
lung cancer [and leukemias (11)]. These
results may well be evincing the influence
exerted on public health by the environmen-
tal impact of mining activities and the effects
of natural radiation. 
In this exploratory study, we have sought
to estimate risk of death for 11 different tumor
sites in the vicinity of 8 installations. For many
of these, we analyzed different areas and time
periods, thereby allowing for numerous com-
parisons. The results must therefore be inter-
preted with caution, because some of the
statistically significant mortality excesses or
deficits found may be attributable to chance.
The validity of death-certificate diagnoses
for investigating cancer is generally accepted
(2,3,18,19). Except for Tarragona, none of
the provinces studied are equipped with pop-
ulation-based cancer registries that would
otherwise enable cancer incidence to be stud-
ied in these areas. In the calculation of per-
son-years, interpolation and extrapolation
techniques had to be employed. We applied
these techniques in the same way to all
provinces and towns included in the various
studies. Hence, any possible deviations inher-
ent in the estimates, will be equally present in
all areas compared. 
Specific methodologic problems are posed
by investigation into relatively rare diseases in
areas adjacent to sources of contamination.
The importance of ascertaining disease-fre-
quency and -distribution in other areas simi-
lar in size to those being studied has been
stressed (20), which we followed in our
design. In general, the areas compared in this
study were rural. We matched reference
towns to exposed towns by sociodemographic
variables; the towns would thus indirectly
maintain their comparability in diagnostic
accuracy and accessibility to the health care
system. Sociodemographic information for
the entire study period was not available.
However, bearing in mind the universal char-
acter of the Spanish National Health System,
there would be no reason to suspect differen-
tial access to health care and diagnosis
between exposed and reference areas.
In theoretical terms, comparison of
SMRs is open to criticism in that, internally,
the SMRs use different standard popula-
tions. Nevertheless, analysis based on com-
parison of mortality rates (rate ratios) via
models that use person-years as offset and
include age yielded equivalent results.
The study of the distance variable seeks to
associate mortality with the nuclear installa-
tion as the putative source of contamination.
Distance to the installation tends to be used as
a surrogate variable for exposure in cases where
dosimetric information or the radiologic his-
tory of an installation’s environs is not forth-
coming (21,22). Indeed in this respect the
study is ecologic, in that individual levels of
exposure are unknown and the inhabitants of
any given town are thus implicitly assumed to
have received similar exposures. There will
inevitably be persons who have resided for part
of their lives in exposed towns and then
moved to nonexposed areas, and vice versa,
which would produce nondifferential misclas-
sification errors. Moreover, information is
lacking on other risk factors associated with
these tumors, such as smoking or exposure to
chemical agents, although we sought to con-
trol for these partly by the town matching
incorporated into the overall design.
In the Garoña area an unexpected,
higher risk of stomach cancer was detected
in both sexes, apparently linked to proximity
to the nuclear power plant. Moreover, there
was a parallel deficit in lung cancer mortality
in this same area. This coincidence is remi-
niscent of the documented cancer mortality
pattern in farmers (23) and could be inter-
preted as a design failure (matching by pro-
portion of farmers) to control for this
component. Yet it is strange that this should
occur solely in the Garoña area and not in
the surroundings of other installations. This,
coupled with the fact that Garoña is situated
in Burgos province—a province with the
highest stomach cancer mortality in Spain—
impels us to recommend an in-depth study.
It would also be advisable to analyze bone
and renal cancer incidence in the vicinity of
Vandellós, because associated mortality
proved higher than expected in towns lying
nearest the plant, although admittedly this
observation was based on very few cases.
The Zorita and Almaraz areas display an
excess of cases of connective tissue cancer.
Taking Spain as reference, the respective
SMRs are 1.48 (95% CI, 0.55–3.23) for
Zorita and 5.22 (95% CI, 2.09–10.75) for
Almaraz. Nonetheless, the location of these
cases (mostly residents of towns situated on
the limits of the study area) and the fact that
cases had already been reported in this sector
before start-up (Table 4), leads us to think
that the causes probably lie outside the
Almaraz plant, although this result, too,
would appear to call for closer study.
In the literature, it is difficult to find stud-
ies that have evaluated and published non-
hematologic tumor incidence and/or mortality
for areas neighboring NPP, and more difficult
still for areas neighboring NFF. The standard
practice is to group these under the heading of
“other tumors” or “solid tumors,” and the
findings published for this umbrella group are
generally negative. Consequently, the informa-
tion to which we could turn to compare our
results was very limited. 
We should like to stress the differences
in our results between the mortality patterns
around NPP and those around NFF. In the
vicinity of NFF, we detected an excess risk of
cancer-related death of 5.6%. This excess is,
in great part, determined by lung cancer
mortality, which we observed exclusively in
men (RR 1.14; 95% CI, 1.03–1.27) and has
been detected in the Andújar and Ciudad
Rodrigo areas. In the previous study, we
reported a higher risk of leukemias in these
same areas (11). To challenge the feasibility
that tobacco use has any influence on this
result—and given that smoking frequencies
could not be included in the analysis—one
could point to the fact that there was no par-
allel rise in bladder cancer mortality, a tumor
likewise associated with cigarette smoking. 
NFF are located in areas with uranium
deposits, areas where mining operations are
carried out and nuclear fuel is manufactured. A
cytogenetic analysis showed a greater frequency
of chromosomal aberrations and an abnormal
DNA-repair response for a population residing
near mines/uranium processing plants versus
an unexposed population, though this was
based on a small study (24,25).
Underlying the findings for areas near
NFF are two phenomena: One concerns the
lung-cancer–related deaths observed in men,
which could be occupational in origin; this
problem has been well documented (26)
thanks to cohort studies covering miners in
the uranium industry (27) and (underground)
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miners in general (28). The other  phenome-
non stems from environmental exposure to
radon produced by the degradation of ura-
nium-238 present in the soil of granite areas,
and to natural radiation (an aspect that could
not be controlled for in this study) and
radioactive waste; and from the consequences
of mining activities on the population (24).
Arguably, each installation might have its
own peculiarities, thus highlighting the limits
on the ability of any generic radiobiologic-
impact assessment to reflect the conditions of
all uranium facilities (10).
In refining the ore to produce uranium
concentrates, a great volume of hazardous
waste is generated, known as tailings. These
tailings are often dumped outdoors. Such
waste contains most of the radionuclides that
are produced by uranium degradation and
continue to be radioactive for hundreds of
years, plus variable quantities of other toxic
substances, which are either present in the
mineral (e.g., heavy metals) or used in extrac-
tion. Radionuclides and chemical toxics can be
dispersed more easily from such dumps than
they could from their original state in the ore,
as a result of hydrologic and atmospheric
processes (29), containment-dam disasters,
and the possibility of improper use in the
preparation of construction materials. Danger
of contamination from tailings is heightened
when dumps are abandoned following mine
closure. To our knowledge, there is not one
single site anywhere in the world in which a
uranium mine has been satisfactorily cleaned.
Residential exposure to radon is an impor-
tant cause of lung cancer in the general popu-
lation (7,26). The interaction between radon
exposure and smoking with regard to lung
cancer exceeded additivity and approaches a
multiplicative effect (30).
Similarly noteworthy is the higher risk of
death due to renal cancer, a tumor that regis-
ters point effect indicators exceeding 1 for all
NFF studied. Excess risk is higher in women
(RR 1.81; 95% CI, 1.21–2.73) than in men
(RR 1.16; 95% CI, 0.84–1.59). Although
these results are difficult to interpret in envi-
ronmental terms, renal toxicity is known to
be the most adverse side effect of exposure to
uranium (31). Dosimetric studies of radon
exposure have shown that the kidney receives
the second highest doses after the lung (7),
and animal studies have shown that radon
exposure can cause renal cancer (32).
Furthermore, some results indicate that resi-
dence in the proximity of mill tailings raises
the frequency of chromosomal aberrations
and DNA-repair deficiencies (29). 
In addition to lung cancer, exposure to
radon has been associated with other types of
tumors (33–35), though there are studies that
conclude the contrary (7). International inci-
dence of myeloid leukemia, renal cancer, and
certain childhood cancers shows a significant
correlation with radon exposure in the home
(33). In one case–control study undertaken in
Italy to evaluate the effect of radon levels,
odds ratios of 2–3 were found for renal can-
cer, in tandem with a statistically significant
dose–response relationship (34). The exis-
tence of a high risk for this tumor has also
been reported for employees of the atomic
weapons establishment (35).
Given the nature of our study, any com-
ments that we might advance to explain these
findings would, in part, be speculative.
Nevertheless, we believe that besides the effects
of natural radiation, the results for NFF could
well be evincing the influence exerted on pub-
lic health by the environmental impact of ura-
nium mining. It is therefore essential that
mechanisms be established to monitor the
incidence of cancer in provinces in which
these two types of facilities are found. We like-
wise recommend that besides nuclear power
plants as such, all radiologic and environmen-
tal monitoring devices and systems deployed
in areas adjacent to installations should also
cover uranium cycle facilities and mill tailings,
and that the ensuing measurements be made
public. Design of any future studies will
require dosimetric measurements for areas sur-
rounding such facilities, efforts to reconstruct
history of exposure, and an attempt to study
the problem from a multidisciplinary point of
view, using biologic exposure markers.
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